FY2025 Earnings Forecast for LXEO Issued By Chardan Capital

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Investment analysts at Chardan Capital lifted their FY2025 earnings per share (EPS) estimates for shares of Lexeo Therapeutics in a report released on Tuesday, May 13th. Chardan Capital analyst G. Livshits now anticipates that the company will post earnings per share of ($2.98) for the year, up from their previous estimate of ($3.06). Chardan Capital has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share.

Other research analysts have also issued reports about the stock. Leerink Partners decreased their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Monday, March 24th. Royal Bank of Canada decreased their price target on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 25th. Finally, HC Wainwright cut their price objective on shares of Lexeo Therapeutics from $23.00 to $15.00 and set a “buy” rating for the company in a report on Friday. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Lexeo Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $20.20.

Lexeo Therapeutics Trading Up 20.0%

LXEO stock opened at $3.24 on Friday. The company’s 50-day simple moving average is $3.07 and its 200-day simple moving average is $4.94. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 52-week low of $1.45 and a 52-week high of $19.50. The firm has a market cap of $107.56 million, a P/E ratio of -1.03 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.19).

Institutional Trading of Lexeo Therapeutics

Hedge funds have recently bought and sold shares of the business. Allostery Investments LP acquired a new stake in shares of Lexeo Therapeutics during the 4th quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Lexeo Therapeutics during the 4th quarter worth approximately $46,000. JPMorgan Chase & Co. increased its holdings in shares of Lexeo Therapeutics by 135.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock worth $93,000 after buying an additional 5,915 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Lexeo Therapeutics during the 4th quarter worth approximately $69,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Lexeo Therapeutics during the 4th quarter worth approximately $72,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.